Scholar Rock Holding (SRRK) Operating Income (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Operating Income of -$102.0 million in Q1 2026, down 11.01% quarter-over-quarter from -$91.9 million in Q4 2025, and down 32.33% on a YoY basis from -$150.8 million in Q1 2025.
Scholar Rock Holding (SRRK) Operating Income (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Operating Income history runs 10 years deep, the most recent figure standing at -$102.0 million for Q1 2026.
- In Q1 2026, Operating Income fell 32.33% year-over-year to -$102.0 million; the TTM figure through Mar 2026 stood at -$409.6 million (down 51.29% YoY), while the FY2025 annual figure was -$384.6 million, down 52.6% from the prior year.
- Operating Income was -$102.0 million for Q1 2026 at Scholar Rock Holding, down from -$91.9 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$6.9 million in Q1 2022 to a low of -$112.1 million in Q2 2025.
- Historically, Operating Income has averaged -$61.4 million across 5 years, with a median of -$58.4 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Operating Income surged 74.52% in 2022, then sank 484.29% in 2023.
- A 5-year view of Operating Income shows it stood at -$40.4 million in 2022, then fell by 18.81% to -$48.0 million in 2023, then tumbled by 44.4% to -$69.4 million in 2024, then tumbled by 32.5% to -$91.9 million in 2025, then slipped by 11.01% to -$102.0 million in 2026.
- The last three Operating Income figures came in at -$102.0 million (Q1 2026), -$91.9 million (Q4 2025), and -$103.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | -102.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.02 Mn |
| Dec 31, 2025 | -91.90 Mn |
| Sep 30, 2025 | -103.55 Mn |
| Jun 30, 2025 | -112.11 Mn |
| Mar 31, 2025 | -77.09 Mn |
| Dec 31, 2024 | -69.36 Mn |
| Sep 30, 2024 | -64.78 Mn |
| Jun 30, 2024 | -59.50 Mn |
| Mar 31, 2024 | -58.42 Mn |
| Dec 31, 2023 | -48.03 Mn |
| Sep 30, 2023 | -43.67 Mn |
| Jun 30, 2023 | -39.08 Mn |
| Mar 31, 2023 | -40.51 Mn |
| Dec 31, 2022 | -40.43 Mn |
| Sep 30, 2022 | -43.86 Mn |
| Jun 30, 2022 | -43.15 Mn |
| Mar 31, 2022 | -6.93 Mn |
| Dec 31, 2021 | -35.36 Mn |
| Sep 30, 2021 | -37.08 Mn |
| Jun 30, 2021 | -30.27 Mn |